Sanjay Chandru Keswani - 13 Feb 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role: Chief Medical Officer
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol: NBIX
Transactions as of: 13 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 17 Feb 2026, 17:44:03 UTC
Previous filing: 04 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Keswani Sanjay Chandru	Chief Medical Officer	6027 EDGEWOOD BEND CT., SAN DIEGO	/s/ Darin Lippoldt, Attorney-in-Fact	17 Feb 2026	0001818524

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NBIX	Stock Option	Award	$0	+35,827		$0.000000	35,827	13 Feb 2026	Common Stock	35,827	$124.12	Direct	F1
transaction	NBIX	Restricted Stock Unit	Award	$0	+6,285		$0.000000	6,285	13 Feb 2026	Common Stock	6,285		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F2	Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3	The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.